Please provide your email address to receive an email when new articles are posted on . A novel TAVR system was safe and effective for adults with severe aortic regurgitation who are not surgical ...

SAN FRANCISCO — Among patients with symptomatic, severe native aortic regurgitation at high surgical risk, the JenaValve Trilogy transcatheter heart valve system (JenaValve Technology) met its primary ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Transcatheter aortic valve replacement (TAVR) is currently a widely used option for patients with severe ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- ...

A steady stream of structural trial data, approvals, reimbursement decisions, and real-world rollouts arrived in 2025.

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

DRAPER, Utah--(BUSINESS WIRE)--Xenter, Inc. (Xenter.io) announced the recent unveiling of its groundbreaking dual sensor investigational guidewire for TAVR procedures at the Transcatheter ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial's ...

SAN FRANCISCO -- One anatomic feature, typically found in women, did not make patients with severe aortic stenosis (AS) better suited for either transcatheter aortic valve replacement (TAVR) or ...